Medical Eligibility Criteria for Contraceptive Use reviews the medical eligibility criteria for use of contraception, offering guidance on the safety and use of different methods for women and men with specific characteristics or known medical conditions. The recommendations are based on systematic reviews of available clinical and epidemiological research. It is a companion guideline to Selected Practice Recommendations for Contraceptive Use. Together, these documents are intended to be used by policy-makers, program managers, and the scientific community to support national programs in the preparation of service delivery guidelines. The fourth edition of this useful resource supersedes previous editions, and has been fully updated and expanded. It includes over 86 new recommendations and 165 updates to recommendations in the previous edition. Guidance for populations with special needs is now provided, and a new annex details evidence on drug interactions from concomitant use of antiretroviral therapies and hormonal contraceptives. To assist users familiar with the third edition, new and updated recommendations are highlighted. Everyone involved in providing family planning services and contraception should have the fourth edition of Medical Eligibility Criteria for Contraceptive Use at hand.

"CDC created U.S. Medical Eligibility Criteria for Contraceptive Use, 2010, from guidance developed by the World Health Organization (WHO) and finalized the recommendations after consultation with a group of health professionals who met in Atlanta, Georgia, during February 2009. This guidance comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. The majority of the U.S. guidance does not differ from the WHO guidance and covers >60 characteristics or medical conditions. However, some WHO recommendations were modified for use in the United States, including recommendations about contraceptive use for women with venous thromboembolism, valvular heart disease, ovarian cancer, and uterine fibroids and for postpartum and breastfeeding women. Recommendations were added to the U.S. guidance for women with rheumatoid arthritis, history of bariatric surgery, peripartum cardiomyopathy, endometrial hyperplasia, inflammatory bowel disease, and solid organ transplantation. The recommendations in this document are intended to assist health-care providers when they counsel women, men, and couples about contraceptive method choice. Although these recommendations are meant to serve as a source of clinical guidance, health-care providers should always consider the individual clinical circumstances of each person seeking family planning services." - P. 1.

This book is a comprehensive, up-to-date reference on general and subspecialty gynecology. Covering all aspects of gynecology commonly encountered in day-to-day practice, this exhaustive and fully updated new edition provides a practical, one-stop reference work for clinicians working in the field. This carefully-designed volume includes ten sections, beginning with comprehensive coverage of office-based gynecology, and continuing on to present disease processes and management information by patient age group. Each chapter includes background information, current recommendations for screening, diagnostic criteria, common and uncommon associated problems, approach to diagnosis, summary of treatment options, and an overview of ICD-10 codes for specific diagnoses. Importantly, many areas that are covered in the handbook as subspecialty problems are pertinent and important information to many of the general practitioners who handle and develop some expertise in these areas. These include ovulation induction, medical management of incontinence, management of abnormal Pap smears, and work-up of abnormal bleeding. The handbook concludes with an easy-to-navigate presentation of minimally-invasive operations, surgical procedures, neoplasms, and pathology. Advantages and risks associated with management of particular diseases are covered, along with multiple tips for avoiding complications. This second edition is fully updated. With extensive updates on cervical cancer screening, pelvic organ prolapse, and more, many chapters will be completely rewritten to reflect the latest guidelines, procedures, and methods of care in women’s health. The text additionally includes two new chapters, covering the impact of COVID on gynecology care, and the work-up and surgical management of chronic pelvic pain. This is an ideal guide for practicing gynecologists, family and internal medicine physicians, physician assistants, nurse practitioners, fellows, residents, medical students, and all women’s health care providers.

The U. S. Selected Practice Recommendations for Contraceptive Use 2013 (U.S. SPR), comprises recommendations that address a select group of common, yet sometimes controversial or complex, issues regarding initiation and use of specific contraceptive methods. These recommendations are a companion document to the previously published CDC recommendations U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 (U.S. MEC). U.S. MEC describes who can use various methods of contraception, whereas this report describes how contraceptive methods can be used. CDC based these U.S. SPR guidelines on the global family planning guidance provided by the World Health Organization (WHO). Although many of the recommendations are the same as those provided by WHO, they have been adapted to be more specific to U.S. practices or have been modified because of new evidence. In addition, four new topics are addressed, including the effectiveness of female sterilization, extended use of combined hormonal methods and bleeding problems, starting regular contraception after use of emergency contraception, and determining when contraception is no longer needed. The recommendations in this report are intended to serve as a source of clinical guidance for health-care providers; health-care providers should always consider the individual clinical circumstances of each person seeking family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. Persons should seek advice from their health-care providers when considering family planning options.

This item is sold in packs of 20. This wheel contains the medical eligibility criteria for starting use of contraceptive methods. It is based on the Medical Eligibility Criteria for Contraceptive Use, Third Edition and its 2008 Update. This update of the MEC Wheel contains 25 new recommendations that tell family planning providers whether a woman presenting with a known medical or physical condition is able to use various contraceptive methods safely and effectively. Notable changes include no restrictions on the use of any method for women diagnosed with mild cirrhosis, chronic hepatitis or who are carriers of viral hepatitis. In addition, the updated wheel includes new guidance on drug interactions. Now, women who take anticonvulsants (except lamotrigine), who are on antiretroviral therapy (except ritonavir-boosted ARVs), or have a deep vein thrombosis and are taking anticoagulant therapy are generally able to use any contraceptive method. The wheel includes recommendations on initiating use of six common types of contraceptives: 1. Combined pills (low dose combined oral contraceptives) 2. Combined injectable contraceptives 3. Progestogen-only pills 4. Progestogen-only injectable, DMPA and NET-EN 5. Progestogen-only implants 6. Copper-bearing IUD.

This document is one of two evidence-based cornerstones of the World Health Organization's (WHO) new initiative to develop and implement evidence-based guidelines for family planning. The first cornerstone, the Medical eligibility criteria for contraceptive use (third edition) published in 2004, provides guidance for who can use contraceptive methods safely. This document, the Selected practice recommendations for contraceptive use (second edition), provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. The recommendations contained in this document are the product of a process that culminated in an expert Working Group meeting held at the World Health Organization, Geneva, 13-16 April 2004.